Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31620610 | 1.00 | MAPK1 (0.59) | MAPK1P4HTMKDM4EL3MBTL1NPC1 | |
| SCHEMBL9901416 | 0.86 | CYP1A2 (0.51) | MAPK1P4HTMKDM4ENPC1RAB9A | |
| SCHEMBL991921 | 0.85 | MAPK1 (0.57) | MAPK1P4HTMKDM4EL3MBTL1RAB9A | |
| SCHEMBL13466852 | 0.85 | MAPK1 (0.57) | MAPK1P4HTMKDM4EL3MBTL1RAB9A | |
| SCHEMBL30402265 | 0.85 | MAPK1 (0.57) | MAPK1P4HTMKDM4EL3MBTL1RAB9A | |
| SCHEMBL25247080 | 0.85 | GAA (0.51) | MAPK1KDM4EHSD17B10POLBTP53 | |
| SCHEMBL30404318 | 0.85 | GAA (0.51) | MAPK1KDM4EHSD17B10POLBTP53 | |
| SCHEMBL1545257 | 0.84 | MAPK1 (0.65) | MAPK1P4HTMKDM4EL3MBTL1POLB | |
| SCHEMBL31296544 | 0.84 | MAPK1 (0.65) | MAPK1P4HTMKDM4EL3MBTL1POLB | |
| SCHEMBL22119231 | 0.83 | MAPK1 (0.56) | MAPK1P4HTMKDM4EL3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4650351-A1 | INHIBITOR OF COMPLEMENT FACTOR B | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| EP-4079734-B1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) | 2025-09-17 | — | — | EP | disclosed |
| EP-4587427-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCERS | BenevolentAI Cambridge Limited (GB) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024149261-A1 | INHIBITOR OF COMPLEMENT FACTOR B | 南京正大天晴制药有限公司 | 2024-07-18 | — | — | WO | disclosed |
| CN-114302886-B | Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024057001-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCERS | Benevolentai Cambridge Limited (GB) | 2024-03-21 | — | — | WO | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4079734-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
| CN-114302886-A | Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20160137653-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
| WO-2016073774-A2 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-9296734-B2 | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-11-12 | — | — | US | disclosed |
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-20140249104-A1 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2014-09-04 | — | — | US | disclosed |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO University Hospital, HF (NO) | 2014-01-30 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012087237-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137653-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | MAPK1 2465/4885P4HTM 1532/4885KDM4E 2099/4885 |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | ABCG2, CYP4F8, CYP3A5 | MAPK1 2893/4885P4HTM 959/4885KDM4E 4228/4885 |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | MAPK1 150/4885P4HTM 2605/4885KDM4E 4148/4885 |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | MAPK1 1670/4885P4HTM 4599/4885KDM4E 4048/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | MAPK1 2422/4885P4HTM 847/4885KDM4E 3564/4885 |
| US-20140249104-A1 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | MAPK1 4156/4885P4HTM 860/4885KDM4E 2699/4885 |
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | MAPK1 1841/4885P4HTM 1890/4885KDM4E 2783/4885 |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | MAPK1 160/4885P4HTM 2527/4885KDM4E 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.